A rapid manufacturing pipeline for BCMA-targeting CAR T cells drastically shortens “vein-to-vein” times, and produces cells that demonstrate encouraging safety results in a phase one trial of patients with relapsed #MultipleMyeloma. #ScienceTranslationalMedicine https://scim.ag/4fd3JaW
Durcabtagene autoleucel, a rapidly manufactured BCMA-directed CAR T cell therapy, was safe and efficacious in relapsed/refractory multiple myeloma.
